[Lipoprotein metabolism disturbances in patients with kidney diseases]

Area of Science:

• Cardiovascular Science
• Nephrology
• Lipid Metabolism

Background:

• Lipoprotein(a) [Lp(a)] is a well-established independent risk factor for atherosclerosis, coronary artery disease, and peripheral vascular diseases.
• Patients with end-stage renal failure (ESRF) exhibit higher serum Lp(a) levels compared to the general population.
• These elevated Lp(a) levels in ESRF patients are independent of their dialysis treatment modality.

Discussion:

• Cardiovascular diseases (CVDs) represent the leading cause of mortality in patients with ESRF.
• The elevated Lp(a) levels in ESRF patients are particularly concerning given the high burden of CVD in this population.
• Understanding the role of Lp(a) in ESRF patients is crucial for risk stratification and management.

Key Insights:

• Lipoprotein(a) is a significant independent risk factor for various vascular diseases.
• End-stage renal failure patients have elevated Lipoprotein(a) levels, irrespective of treatment.
• Cardiovascular disease is the primary cause of death in ESRF patients, highlighting the importance of factors like Lp(a).

Outlook:

• Further research is warranted to explore the precise mechanisms by which Lp(a) influences cardiovascular disease in ESRF patients.
• Investigating therapeutic strategies to lower Lp(a) levels in ESRF patients may reduce cardiovascular mortality.
• Continued monitoring of Lp(a) levels could aid in personalized risk assessment and preventative care for ESRF patients.